APA (7th ed.) Citation

T, E., CM, E., D, Z., EL, C., AY, R., Z, A., . . . MG, K. (2022). TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nature communications, 13(1), 5676. https://doi.org/10.1038/s41467-022-33137-8

Chicago Style (17th ed.) Citation

T, Erazo, et al. "TP53 Mutations and RNA-binding Protein MUSASHI-2 Drive Resistance to PRMT5-targeted Therapy in B-cell Lymphoma." Nature Communications 13, no. 1 (2022): 5676. https://doi.org/10.1038/s41467-022-33137-8.

MLA (9th ed.) Citation

T, Erazo, et al. "TP53 Mutations and RNA-binding Protein MUSASHI-2 Drive Resistance to PRMT5-targeted Therapy in B-cell Lymphoma." Nature Communications, vol. 13, no. 1, 2022, p. 5676, https://doi.org/10.1038/s41467-022-33137-8.